The expanding phenotype of hypokalemic periodic paralysis in a Japanese family with p.Val876Glu mutation in CACNA1S.


Journal

Molecular genetics & genomic medicine
ISSN: 2324-9269
Titre abrégé: Mol Genet Genomic Med
Pays: United States
ID NLM: 101603758

Informations de publication

Date de publication:
04 2020
Historique:
received: 12 07 2019
revised: 17 01 2020
accepted: 30 01 2020
pubmed: 28 2 2020
medline: 7 4 2021
entrez: 28 2 2020
Statut: ppublish

Résumé

Hypokalemic periodic paralysis (HypoPP) is an autosomal dominant disease characterized by the episodic weakness of skeletal muscles and hypokalemia. More than half patients with HypoPP carry mutations in CACNA1S, encoding alpha-1 subunit of calcium channel. Few reports have documented the non-neuromuscular phenotypes of HypoPP. The proband is a Japanese woman who developed HypoPP at 6 years of age. An excessive insulin secretion with the oral glucose tolerance test rationalized that she had experienced frequent attacks of paralysis on high-carbohydrate diets. Voglibose and acetazolamide effectively controlled her paralytic episodes. Her 8-year-old son and 2-year-old daughter started showing the paralytic symptoms from 4 and 2 years of age, respectively. Laboratory tests revealed high concentrations of creatinine kinase in serum and elevated renin activities in plasma of these children. The targeted sequencing confirmed that these three patients had an identical heterozygous mutation (p.V876E) in CACNA1S. Our data indicate that the p.V876E mutation in CACNA1S contributes to the early onset of neuromuscular symptoms and unusual clinical phenotypes of HypoPP.

Sections du résumé

BACKGROUND
Hypokalemic periodic paralysis (HypoPP) is an autosomal dominant disease characterized by the episodic weakness of skeletal muscles and hypokalemia. More than half patients with HypoPP carry mutations in CACNA1S, encoding alpha-1 subunit of calcium channel. Few reports have documented the non-neuromuscular phenotypes of HypoPP.
METHODS
The proband is a Japanese woman who developed HypoPP at 6 years of age. An excessive insulin secretion with the oral glucose tolerance test rationalized that she had experienced frequent attacks of paralysis on high-carbohydrate diets.
RESULTS
Voglibose and acetazolamide effectively controlled her paralytic episodes. Her 8-year-old son and 2-year-old daughter started showing the paralytic symptoms from 4 and 2 years of age, respectively. Laboratory tests revealed high concentrations of creatinine kinase in serum and elevated renin activities in plasma of these children. The targeted sequencing confirmed that these three patients had an identical heterozygous mutation (p.V876E) in CACNA1S.
CONCLUSION
Our data indicate that the p.V876E mutation in CACNA1S contributes to the early onset of neuromuscular symptoms and unusual clinical phenotypes of HypoPP.

Identifiants

pubmed: 32104981
doi: 10.1002/mgg3.1175
pmc: PMC7196457
doi:

Substances chimiques

CACNA1S protein, human 0
Calcium Channels, L-Type 0

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1175

Informations de copyright

© 2020 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.

Références

Mol Genet Genomic Med. 2020 Apr;8(4):e1175
pubmed: 32104981
Neurology. 2009 May 5;72(18):1544-7
pubmed: 19118277
J Neurol Sci. 2011 Oct 15;309(1-2):9-11
pubmed: 21855088
Neurology. 2004 Nov 9;63(9):1647-55
pubmed: 15534250
J Formos Med Assoc. 2015 Apr;114(4):377-8
pubmed: 23948435
Intern Med. 2004 Mar;43(3):218-22
pubmed: 15098604
J Hum Genet. 2009 Nov;54(11):660-4
pubmed: 19779499
Muscle Nerve. 2018 Apr;57(4):522-530
pubmed: 29125635
Brain. 2001 Jun;124(Pt 6):1091-9
pubmed: 11353725
Diabetologia. 2013 Feb;56(2):340-9
pubmed: 23229155
J Gen Physiol. 2017 Dec 4;149(12):1139-1148
pubmed: 29114033
BMJ Case Rep. 2017 Aug 10;2017:
pubmed: 28798241
Arch Intern Med. 2004 Jul 26;164(14):1561-6
pubmed: 15277290

Auteurs

Mari Kurokawa (M)

Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Michiko Torio (M)

Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Kazuhiro Ohkubo (K)

Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Vlad Tocan (V)

Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Noriko Ohyama (N)

Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Naoko Toda (N)

Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Kanako Ishii (K)

Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Kei Nishiyama (K)

Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Yuichi Mushimoto (Y)

Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Ryuichi Sakamoto (R)

Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Maki Nakaza (M)

Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Osaka, Japan.

Riho Horie (R)

Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Osaka, Japan.

Tomoya Kubota (T)

Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Osaka, Japan.

Masanori P Takahashi (MP)

Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Osaka, Japan.

Yasunari Sakai (Y)

Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Masatoshi Nomura (M)

Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Fukuoka, Japan.

Shouichi Ohga (S)

Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH